The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Open accessAbstract
BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of <400 copies per milliliter), histologic improvement, serologic response, normalization of alanine aminotransferase levels, and development of resistance mutations. RESULTS: At week 48, in both studies, a significantly higher proportion of patients receiving tenofovir DF than of those receiving adefovir dipivoxil had reached the primary end point (P<0.001). Viral suppression occurred in more HBeAg-negative patients receiving tenofovir DF than patients receiving adefovir dipivoxil (93% vs. 63%, P<0.001) and in more HBeAg-positive patients receiving tenofovir DF than patients receiving adefovir dipivoxil (76% vs. 13%, P<0.001). Significantly more HBeAg-positive patients treated with tenofovir DF than those treated with adefovir dipivoxil had normalized alanine aminotransferase levels (68% vs. 54%, P=0.03) and loss of hepatitis B surface antigen (3% vs. 0%, P=0.02). At week 48, amino acid substitutions within HBV DNA polymerase associated with phenotypic resistance to tenofovir DF or other drugs to treat HBV infection had not developed in any of the patients. Tenofovir DF produced a similar HBV DNA response in patients who had previously received lamivudine and in those who had not. The safety profile was similar for the two treatments in both studies. CONCLUSIONS: Among patients with chronic HBV infection, tenofovir DF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with adefovir dipivoxil at a daily dose of 10 mg through week 48. (ClinicalTrials.gov numbers, NCT00116805 and NCT00117676.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Self-citationA Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Self-citationAdefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Self-citationLamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Self-citationSpecial Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, Y.-F., Kao, J.-H., Piratvisuth, T., Chan, H. L. Y., Chien, R.-N., Liu, C.-J., Gane, E., Locarnini, S., Lim, S.-G., Han, K.-H., et al. (2012) · Hepatology International · doi:10.1007/s12072-012-9365-4 · Cited by 1,038
Self-citationHepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & Locarnini, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 706
Chronic Hepatitis B Infection: A Review
Tang, L. S. Y., Covert, E., Wilson, E., & Kottilil, S. (2018) · JAMA · doi:10.1001/jama.2018.3795 · Cited by 657
Chang, T.-T., Lai, C.-L., Yoon, S. K., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., et al. (2010) · Hepatology · doi:10.1002/hep.23327 · Cited by 588
Self-citationTenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Pan, C. Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., Zhang, H., Zou, H., Zhu, B., Zhao, W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508660 · Cited by 573
Buti, M., Gane, E., Seto, W. K., Chan, H. L. Y., Chuang, W.-L., Stepanova, T., Hui, A.-J., Lim, Y.-S., Mehta, R., Janssen, H. L. A., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30107-8 · Cited by 554
Self-citationPapatheodoridis, G. V., Chan, H. L.-Y., Hansen, B. E., Janssen, H. L. A., & Lampertico, P. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.002 · Cited by 511
Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta
Wedemeyer, H., Yurdaydìn, C., Dalekos, G. N., Erhardt, A., Çakaloğlu, Y., Değertekin, H., Gürel, S., Zeuzem, S., Zachou, K., Bozkaya, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0912696 · Cited by 488
Self-citationChan, H. L. Y., Fung, S., Seto, W. K., Chuang, W.-L., Chen, C.-Y., Kim, H. J., Hui, A. J., Janssen, H. L. A., Chowdhury, A., Tsang, T. Y. O., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30024-3 · Cited by 469
Self-citationThree-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Self-citationEASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Overview of hepatitis B viral replication and genetic variability
Tong, S., & Revill, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.027 · Cited by 417
Liver regeneration — mechanisms and models to clinical application
Forbes, S. J., & Newsome, P. N. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.97 · Cited by 411
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Marcellin, P., Ahn, S. H., Ma, X., Caruntu, F. A., Tak, W. Y., Elkashab, M., Chuang, W.-L., Lim, S.-G., Tabak, F., Mehta, R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.09.043 · Cited by 342
Self-citationvan Bömmel, F., de Man, R. A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., Erhardt, A., Hüppe, D., Stein, K., Trojan, J., et al. (2010) · Hepatology · doi:10.1002/hep.23246 · Cited by 330
Self-citationLiaw, Y.-F., Sheen, I.-S., Lee, C.-M., Akarca, U. S., Papatheodoridis, G. V., Wong, F. S.-H., Chang, T.-T., Horban, A., Wang, C., Kwan, P., et al. (2011) · Hepatology · doi:10.1002/hep.23952 · Cited by 316
Self-citationMarcellin, P., Bonino, F., Lau, G. K. K., Farci, P., Yurdaydin, C., Piratvisuth, T., Jin, R., Gurel, S., Lu, Z.-M., Wu, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.006 · Cited by 315
Self-citationButi, M., Tsai, N., Petersen, J., Flisiak, R., Gurel, S., Krastev, Z., Aguilar Schall, R., Flaherty, J. F., Martins, E. B., Charuworn, P., et al. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3486-7 · Cited by 297
Self-citationHepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management
Chang, M.-L., & Liaw, Y.-F. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.033 · Cited by 296
Chang, M.-H. (2007) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2007.01.013 · Cited by 296
Kim, W. R., Berg, T., Asselah, T., Flisiak, R., Fung, S., Gordon, S. C., Janssen, H. L. A., Lampertico, P., Lau, D., Bornstein, J. D., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.012 · Cited by 296
Self-citationGuideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
Hou, J., Wang, G., Wang, F., Cheng, J., Ren, H., Zhuang, H., Sun, J., Li, L., Li, J., Meng, Q., et al. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00019 · Cited by 270
Garg, H., Sarin, S. K., Kumar, M., Garg, V., Sharma, B. C., & Kumar, A. (2011) · Hepatology · doi:10.1002/hep.24109 · Cited by 264
Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D. K. H., Pham, B., Ungar, W. J., Einarson, T. R., Heathcote, E. J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.042 · Cited by 259
Self-citationGish, R. G., Given, B. D., Lai, C.-L., Locarnini, S. A., Lau, J. Y. N., Lewis, D. L., & Schluep, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.008 · Cited by 259
Antiviral Drug Resistance: Mechanisms and Clinical Implications
Strasfeld, L., & Chou, S. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.001 · Cited by 254
Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H.-W., Gurel, S., Caruntu, F. A., Flaherty, J. F., Massetto, B., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.028 · Cited by 147
Self-citationThe cost-effectiveness of screening for chronic hepatitis B infection in the United States
Eckman, M. H., Kaiser, T. E., & Sherman, K. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir199 · Cited by 80
Metadata
- Authors
- Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas, O. O., Shiffman, M. L., Trinh, H., Washington, M. K., Sorbel, J., Anderson, J., Snow-Lampart, A., Mondou, E., Quinn, J., & Rousseau, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2442-2455
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2059560167
- Cited by
- 1,181
- References
- 30
- FWCI
- 67.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.